Research Article Details
| Article ID: | A27648 |
| PMID: | 17764776 |
| Source: | Diabetes Res Clin Pract |
| Title: | Probable NAFLD, by ALT levels, and diabetes among Filipino-American women. |
| Abstract: | BACKGROUND: Studies have shown alanine aminotransferase (ALT), a marker for non-alcoholic fatty liver disease (NAFLD), predicts type 2 diabetes (T2DM). OBJECTIVE: To examine the association between probable NAFLD and T2DM in non-obese, non-alcoholic consuming Filipino-American women aged 48-73 years. RESEARCH DESIGN AND METHODS: The UCSD Filipino Women's Health Study measured glucose, hepatic enzymes, adiponectin and visceral fat (VAT) during clinical visits (1995-2002). We defined T2DM by 1999 WHO criteria and probable NAFLD as ALT >31 U/L. RESULTS: Prevalence of T2DM was 34.4% and probable NAFLD was 17.2%. Women with T2DM (n=56) had higher VAT, total:HDL cholesterol, SBP, fasting glucose and insulin, postchallenge glucose, ALT (28.7 U/L versus 19.1 U/L, p<0.0001), GGT, AST, and probable NAFLD (32.1% versus 9.35%, p=0.0002) and lower adiponectin than those without T2DM (n=107). GGT (p=0.0008) and ALT (p=0.002) were associated with increasing VAT levels. Probable NAFLD was independently associated with T2DM (AOR 6.32, 95% CI 2.2-18.0), after adjusting for risk factors. CONCLUSION: Probable NAFLD was elevated and associated with T2DM, independent of VAT, adiponectin and other risk factors. ALT may serve as a useful marker for NAFLD or diabetes risk in Filipino women. |
| DOI: | 10.1016/j.diabres.2007.07.012 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |